key: cord-0978481-2bgwdbrk
authors: Li, Yebei; Rao, Meiying; Xu, Gaosi
title: New-Onset Acute Kidney Disease Post COVID-19 Vaccination
date: 2022-05-09
journal: Vaccines (Basel)
DOI: 10.3390/vaccines10050742
sha: ae0adb1989194ee3d34c6a58ea3444d1cc8b9656
doc_id: 978481
cord_uid: 2bgwdbrk

The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused an exceptional setback to the global economy and health. Vaccination is one of the most effective interventions to markedly decrease severe illness and death from COVID-19. In recent years, there have been increasingly more reports of new acute kidney injury (AKI) after COVID-19 vaccination. Podocyte injury, IgA nephropathy, vasculitis, tubulointerstitial injury, and thrombotic microangiopathy appear to be the main pathological phenotypes. Nonetheless, whether the link between the COVID-19 vaccine and acute kidney disease (AKD) is causal or coincidental remains to be verified. Here, we generalize some hypotheses for the emergence of AKD and its pathogenesis in response to certain COVID-19 vaccines. In fact, the enormous benefits of mass vaccination against COVID-19 in preventing COVID-19 morbidity and mortality cannot be denied. The purpose of this review is to assist in the clinical assessment and management of AKD following COVID-19 vaccination.

With the ongoing coronavirus disease 2019 (COVID- 19) pandemic and the emergence of new variants of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), the rapid development of effective and safe preventive vaccines is urgently required to control disease outbreaks [1, 2] . Over the past 2 years, hundreds of COVID-19 vaccine candidates have been developed, tested, and finally rolled out, including protein-based vaccines (Novavax), inactivated vaccines (Sinovac Life Science), viral vector vaccines (Janssen, Oxford-AstraZeneca), and mRNA vaccines (Pfizer/BioNtech, Moderna, CureVac) ( Figure 1 ) [2, 3] . Among them, mRNA-based drugs are new but not unknown [4] . mRNA vaccines deliver transgenic mRNA through lipid nanoparticles, which act as carriers. Once injected, the mRNA is translated into the target protein in vivo, resulting in a strong immune response, and a 2-dose regimen confers 95% protection against COVID-19 [5] . To date, large phase III and IV trials have found these vaccines to have a good safety profile, with few serious reactions [3, [6] [7] [8] [9] . Common short-term adverse events include local injection site reactions, fever, fatigue, generalized pain, and headache [6, 10] .

However, since mass vaccination, there have been a few case reports of acute kidney injury (AKI), acute kidney disease (AKD), proteinuria, edema, gross hematuria, and other renal side effects requiring hospitalization after COVID-19 vaccinations [11] . Serum creatinine (Scr) levels and proteinuria recovered within 3 months of treatment in most patients. The vast majority of cases occurred after mRNA vaccine and adenoviral vector injection, and a few cases of glomerulonephritis associated with inactivated virus vaccines have also been reported.

In this review, we summarize the clinical features of AKD after vaccination, and elaborate on the possible mechanisms of AKD after COVID-19 vaccination. Figure 1 . SARS-CoV-2 and the main types of vaccines that may trigger AKD. SARS-CoV-2 is a positive-sense single-stranded RNA virus with a lipid bilayer consisting of the spike S protein and membrane and envelope proteins. mRNA vaccines deliver transgenic mRNA through lipid nanoparticles as carriers. Viral vector vaccines utilize adenovirus and integrate genetic material from SARS-CoV-2 into its genome. Inactivated vaccines involve SARS-CoV-2 that has been killed by physical or chemical means. Figure 1 . SARS-CoV-2 and the main types of vaccines that may trigger AKD. SARS-CoV-2 is a positive-sense single-stranded RNA virus with a lipid bilayer consisting of the spike S protein and membrane and envelope proteins. mRNA vaccines deliver transgenic mRNA through lipid nanoparticles as carriers. Viral vector vaccines utilize adenovirus and integrate genetic material from SARS-CoV-2 into its genome. Inactivated vaccines involve SARS-CoV-2 that has been killed by physical or chemical means.

In this review, we performed a literature search through the electronic database, including Medline/PubMed, EMBASE, and Web of Science (WOS) before February 2022, using the following keywords: ("acute kidney injury" OR "acute kidney disease" OR "glomerulonephritis") AND ("COVID-19" OR 2019-nCoV" OR "novel corona virus" OR "SARS-CoV-2" OR "coronavirus") AND ("vaccine" OR "vaccination").

According to the Kidney Disease: Improving Global Outcomes (KDIGO) criteria, AKI stage 1 is defined as a 0.3 mg/dL increase in Scr within 48 h or a 1.5 to 1.9 times increase in Scr from baseline within 7 days, AKI stage 2 is defined as a 2 to 2.9 times increase in Scr within 7 days from baseline, and AKI stage 3 is defined as a 3 times or more increase in Scr within 7 days from baseline or initiation of renal replacement therapy (RRT) [12, 13] . AKD is defined as a condition of acute or subacute damage and/or loss of renal function between 7 and 90 days after exposure to an AKI initiating event [14] . AKD lasting more than 90 days is considered to be chronic kidney disease (CKD) [14] . The baseline Scr was determined by a median Scr within 8 to 365 days prior to admission. Because of inaccurate and missing urine output records in electronic health records, we did not use the urine output criteria in the KDIGO guidelines to define AKI [15] .

As of 28 February 2022, we found a total of 38 published articles (53 cases) on AKI after SARS-CoV-2 vaccination (Table 1) [11, . Only one case clearly identified an increase in Scr and a resolve within 7 days after vaccination [30] . Scr returned to baseline within 90 days in 37 patients, and no outcomes were recorded in 6 patients. Seven patients did not respond. There were 53 cases in total, including 47 (89%) cases of new kidney involvements and 6 (11%) cases of relapse. Minimal change disease (MCD) was the most common pathology (13 (25%): 11 new, 2 relapse), followed by IgA nephropathy (IgAN) (11 (21%): 9 new, 2 relapse), acquired thrombotic thrombocytopenic purpura (aTTP) (8 (15%): all new), and anti-neutrophil cytoplasmic autoantibodies (ANCA) vasculitis (8 (15%): all new). Other diagnosed diseases included acute interstitial nephritis (AIN) in four new cases, membranous nephropathy (MN) in four cases (two new, two relapse), anti-glomerular basement membrane (anti-GBM) nephritis in three cases (all new), ANCA-negative granulomatous vasculitis in one new case, and leukocytoclastic vasculitis in one new case. The mean age was 58 years (standard deviation 18), and 64% were male.

The Pfizer-BioNTech (mRNA) vaccine was the most common vaccine used (27/53 patients, 51%), followed by Moderna (mRNA) (16/53 patients, 30%), AstraZeneca (Adenovirus vector) (5/53 patients, 9%), Sinovac Life Science (Inactivated virus) (3/53 patients, 6%), and Janssen (Adenovirus vector) (3/53 patients, 6%). Of the 53 patients, 26 patients (49%) had an increase in Scr after the first dose, 25 patients (47%) after the second dose, and 2 patients (4%) after both doses.

Of all the cases reported in the literature, MCD was the most common pathological type of AKD after COVID-19 vaccinations, with a total of 13 cases (11 new and 2 relapse). Six patients had acute renal tubular and/or interstitial injury. Ten patients developed AKD after the first vaccination, and three developed AKD after the second dose. Edema is the most common symptom. All patients received steroids therapy, and one patient also underwent hemodialysis [16] . A patient with relapsed MCD who did not respond to high-dose steroids received rituximab (RTX), to which the patient responded [11] . In total, 11 patients achieved complete remission (CR) or partial remission (PR) within 3 months of treatment, 1 had no response [20] , and 1 had no follow-up records [21] .

Eleven cases of IgAN (nine new onset, two relapse) were reported in the literature, of which only one patient could be identified with AKI without AKD [30] . One case was complicated with AIN [11] . Gross hematuria was the most common presentation. Six patients (four new, two relapse) received conservative treatment, four achieved CR, one did not achieve normal Scr, and one had no follow-up records. The other five new-onset patients were treated with steroids, three patients responded to treatment, and two patients had no follow-up records.

MN developed in four patients (two new and two relapse), and three were serum anti-phospholipase A2 receptor (PLA2R) antibody positive. All patients had symptoms of edema. One new-onset patient received conservative treatment with no remission within 60 days [26] . The other new case developed MN and AKD after the first mRNA (Pfizer-BioNTech) vaccination, achieved partial remission after administration of renin-angiotensin system blockade (RASB), and Scr did not return to baseline levels. Edema reappeared after the second mRNA (Moderna) vaccination, and Scr remained at 1.15 mg/dL [27] . The patient was subsequently given rituximab (RTX) and achieved a PR. One relapse case responded to tacrolimus (TAC), and Scr did not return to baseline during the last follow-up [11] . The other relapsed patient had no records of treatment or follow-up [42] .

According to reports in the literature, there have been three cases of typical new-onset anti-GBM nephritis, accompanied by gross hematuria, hypertension, anorexia, nausea, fever, and other symptoms. One case did not respond to mycophenolate and steroids, and his Scr level continued to rise [11] . Two patients received cyclophosphamide (CyC), plasma exchange (PLEX), and pulse methylprednisolone therapy, one patient did not respond and continued dialysis [32] , and the other one patient had no follow-up records [29] .

In the literature, eight cases were new-onset ANCA-associated vasculitis, five cases were associated with myeloperoxidase (MPO), and three cases with proteinase 3 (PR3). In addition, there was one report of ANCA-negative granulomatous vasculitis following the first dose of adenoviral vector (AstraZeneca) vaccination, and the patient's Scr returned to normal within 2 months [39] . All 3 patients with confirmed PR3-ANCA vasculitis developed symptoms within 1 week after the second dose of mRNA vaccine and were then admitted to hospital for treatment. One case received RTX, CyC, PSL, and hemodialysis treatment, and received hemodialysis without remission. Further, 1 case received high-dose glucocorticoids, CyC, and PLEX, and achieved Scr remission within 3 weeks, and 1 case received pulse methylprednisolone therapy, RTX, CyC, and PLEX, and Scr decreased to 1.5 mg/dL within 10 weeks. From the literature, both MPO-ANCA and ANCA-negative patients with granulomatous vasculitis show improved Scr after treatment.

According to the statistics, only one of the eight patients was reported after the second vaccination [47] . The main symptoms included fever, headache, fatigue, ecchymosis on the limbs, and gastrointestinal reactions, which usually appeared 1 to 2 weeks after vaccination. Except for the one case reported by Al Rawahi et al. [51] , all other cases were immediately treated with PLEX and immunosuppressive therapy, such as corticosteroids, RTX, etc., and the clinical effects were generally good. Additionally, in three cases, the first dose of the COVID-19 vaccine induced high titers of neutralizing IgG against SARS-CoV-2 [45, 49, 51] . ADAMTS13 (A Disintegrin And Metalloproteinase with a ThromboSpondin type 1 motif, member 13) activity levels were markedly reduced and its inhibitor's titer was increased in some cases [45] [46] [47] 49] . Hence, some researchers speculated that in patients without underlying diseases, de novo aTTP was associated with COVID-19 vaccination [49, 51] .

The temporal association between intramuscular vaccination and the development of MCD speculates that a cell-mediated immune response may be a trigger for podocyte injury [20, 53] . All 12 patients with MCD reported in the literature were over 60 years of age, developed AKD within 2 weeks of vaccination, and steroids appeared to be effective in achieving rapid remission (Table 1) . Typically, following vaccination, the vaccine's antigens are taken up by dendritic cells and then presented to T cell receptors on naive T cells [54] . This leads to the activation of antigen-specific effector T cells, peaking 7 to 14 days after vaccination [55] . Studies have also confirmed that during viral infection, cellular immune responses can be observed within about 1 week after infection, but T cell activation can occur 2-3 days earlier [56, 57] . This answers the question of whether it is reasonable for a COVID-19 vaccine to elicit a cell-mediated response 3-4 days after administration.

Although the exact pathogenesis of MCD remains unclear, podocyte damage caused by circulating factors released by activated T lymphocytes appears to be decisive ( Figure 2) [58, 59] . During active stages of MCD, T cell subsets are imbalanced, and circulating CD8+ suppresses the prevalence of T cells, which is exacerbated by cytokine-induced damage [60] . Compared with conventional vaccines, mRNA vaccines are expected to provoke higher antibody responses and stronger CD8+ T and CD4+ T cell reactions, including higher chemokine and cytokine production [61, 62] . The resulting irregular permeability factors can alter glomerular permeability and lead to marked proteinuria and kidney injury [53] . CD8+ suppresses the prevalence of T cells, which is exacerbated by cytokine-induced damage [60] . Compared with conventional vaccines, mRNA vaccines are expected to provoke higher antibody responses and stronger CD8+ T and CD4+ T cell reactions, including higher chemokine and cytokine production [61, 62] . The resulting irregular permeability factors can alter glomerular permeability and lead to marked proteinuria and kidney injury [53] .

Proposed mechanisms of podocyte injury caused by COVID19 vaccination. Vaccination stimulates antigen-presenting cells (APCs) and B cells, which in turn activate T cells through antigen presentation and cytokine production. A decrease in CD4+ T helper (Th) cells is associated with the prevalence of CD8+ cytotoxic T cells, and an imbalance between Th2 and Th1 cells is associated with an increase in Th2-specific interleukin-13 (IL-13) production, and Th17. In contrast to increased cellular activity, the frequency and function of regulatory T cells (Tregs) decreased. Permeability proteins, such as cytokines and autoantibodies, can directly affect podocytes, leading to loss of foot processes and disruption of the glomerular permeability barrier. In addition, the vaccine can also affect podocytes through specific toll-like receptors (TLRs), and angiotensin conversion enzyme 2 (ACE2). The figure refers to the pathogenesis of minimal change disease by Vivarelli et al [53] .

Another hypothesis we speculate might be relevant is that type 2 helper T cells (Th2) indirectly induce tissue cell damage through hypersensitivity reactions via nucleic acid (NA) sensors. Previous study has demonstrated that T cells sensing their own NAs can trigger and amplify allergic inflammation independent of known NA sensors in innate immunity [63] . Muscle cells presenting viral mRNA-derived products on major histocompatibility complex class I are eliminated by CD8+ T cells, and self-NA released by dead muscle cells may directly induce T cell co-stimulation. This may be followed by Th2 differentiation and Th2-mediated allergic inflammation, causing podocytopathy [23] . Proposed mechanisms of podocyte injury caused by COVID19 vaccination. Vaccination stimulates antigen-presenting cells (APCs) and B cells, which in turn activate T cells through antigen presentation and cytokine production. A decrease in CD4+ T helper (Th) cells is associated with the prevalence of CD8+ cytotoxic T cells, and an imbalance between Th2 and Th1 cells is associated with an increase in Th2-specific interleukin-13 (IL-13) production, and Th17. In contrast to increased cellular activity, the frequency and function of regulatory T cells (Tregs) decreased. Permeability proteins, such as cytokines and autoantibodies, can directly affect podocytes, leading to loss of foot processes and disruption of the glomerular permeability barrier. In addition, the vaccine can also affect podocytes through specific toll-like receptors (TLRs), and angiotensin conversion enzyme 2 (ACE2). The figure refers to the pathogenesis of minimal change disease by Vivarelli et al [53] .

Another hypothesis we speculate might be relevant is that type 2 helper T cells (Th2) indirectly induce tissue cell damage through hypersensitivity reactions via nucleic acid (NA) sensors. Previous study has demonstrated that T cells sensing their own NAs can trigger and amplify allergic inflammation independent of known NA sensors in innate immunity [63] . Muscle cells presenting viral mRNA-derived products on major histocompatibility complex class I are eliminated by CD8+ T cells, and self-NA released by dead muscle cells may directly induce T cell co-stimulation. This may be followed by Th2 differentiation and Th2-mediated allergic inflammation, causing podocytopathy [23] . Nevertheless, the study by Sahin et al. found that the COVID-19 mRNA vaccine elicited a cytokine response involving Th1 T cell responses [62, 64] .

Furthermore, SARS-CoV-2 can penetrate proximal tubular cells through ligation with angiotensin conversion enzyme 2 (ACE2) and CD147-spike protein to cause severe AKI, and can also penetrate podocytes through ligation with ACE2, resulting in podocyte dysfunction [65, 66] . In addition, SARS-CoV-2 can also unbalance renin-angiotensin-aldosterone system (RAAS) activation, promoting inflammation, glomerular dysfunction, fibrosis, and vasoconstriction [66] . However, whether the vaccine is related to ACE2 and RAAS is unclear.

Influenza and rabies vaccines based on viral mRNAs have been described to possibly lead to an increase in ANCA, contributing to the development of ANCA-associated vasculitis [67] . Moreover, it was confirmed that the ANCA response was significantly reduced after the treatment of vaccinees with ribonuclease. Scientists have found that in the context of COVID-19, a host response to viral RNA can directly cause ANCA-associated vasculitis (AAV) and an autoimmune response [68] [69] [70] . COVID-19 mRNA vaccination induced a stronger response of the innate immune system after the second booster compared with primary immunization [71] . The heightened innate immune response observed after the second vaccination with BNT162b2 mRNA vaccine may be an inducer of MPO-ANCA and PR3 autoantibodies [34] . Toll-like receptors (TLRs) can be expressed on leukocyte membranes and play an important role in inflammatory responses, recognizing viral antigens and promoting immune system activation. In AAV, major toll-like receptor 2 (TLR2) and toll-like receptor 9 (TLR9) activation can provoke autoimmunity [72] . Interestingly, Kumar et al. suggested that TLR2 was activated by a robust and specific immune response of immunodominant cytotoxic T-lymphocyte (CTL) to the spike glycoprotein of SARS-CoV2 (also produced by the COVID-19 vaccine) [73] . Messenger RNA vaccines could act as both antigen and adjuvant due to their intrinsic immunostimulatory properties of RNA; thus, they can be recognized by endosomal TLRs and cytosolic inflammasome components [64] . Therefore, the occurrence of AAV in the context of COVID-19 mRNA is highly relevant compared with non-mRNA vaccinations, but further experiments are required to verify the mechanism of the link between autoimmunity and a COVID-19 vaccine.

Some scholars have speculated that antiphospholipid antibodies (APLs) may be part of the cause of thrombosis after COVID-19 vaccination, by triggering the type I interferon response associated with APLs' production [74, 75] . It binds directly to platelets by inhibiting the anticoagulant pathway of protein C, triggers the coagulation cascade, and appears to be associated with abnormal activation of immune responses involving the complement cascade [74] . Thrombocytopenia and platelet activation have been reported following the administration of adenoviral gene transfer vectors [76] . Thrombocytopenia also occurred after treatment with some anti-sense oligonucleotides [77] . Based on the above background, another hypothesis speculates that the activation of platelets by adenovirus-platelet-leukocyte complexes, mediated by von Willebrand factor (VWF) and P-selectin, may lead to accelerated clearance of platelets in the liver [75, 78] .

However, the virus in viral vector vaccines is replication-incomparable and the circulating virus disappears 7-14 days after vaccination, so the viral localization to the central nervous system and digestive system causing thrombosis is unlikely [79] . In addition, Greinacher et al. suggested that the rare occurrence of VITT was mediated by platelet factor 4 (PF4)-dependent platelet-activating antibodies, which in turn stimulate platelets via their Fcγ receptors [80, 81] . Immune complexes containing PF4 can be recognized by C1q, which binds to the Fc portion of IgG molecules. This results in C3 activation, expansion of the complement response, and production of downstream proinflammatory mediators and effectors, ultimately leading to enhanced thrombus inflammation.

A previous case reported that a patient who presented with profound left upper arm pain after COVID-19 mRNA vaccination had an increased serum creatine kinase concentration, indicating skeletal muscle damage and inflammation (myositis) [82] . There is also evidence of renal biopsies from post-vaccination patients showing massive rhabdomyolysisinduced myoglobin casting, which may contribute to worsening renal function [34] .

This review has limitations. First, most of the literature is from reported single-case studies, and we cannot infer a causal relationship between vaccines and AKD. There may be potential undetected confounding factors. Second, there may be many unreported cases that may not represent the true incidence of AKD. Third, the mechanism is unproven, with only a combination of hypotheses derived from case reports and literature.

Despite these reported cases of AKD, the protective role of COVID-19 vaccination far outweighs any risks identified so far. In conclusion, the occurrence of AKD is relatively rare following COVID-19 vaccination. If some symptoms, such as hematuria, foamy urine, and edema, can be detected in an early phase, patients will benefit from a timely treatment of the primary disease, such as steroids. Further research is warranted to better understand the causes and mechanisms of AKD after COVID-19 vaccination.

Author Contributions: Y.L. conducted data collection and wrote the manuscript. M.R. conducted data collection. G.X. was responsible for the idea, funds, and paper revision. All authors have read and agreed to the published version of the manuscript. 

BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans

A Review of the Progress and Challenges of Developing a Vaccine for COVID-19

Peiffer-Smadja, N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review

Direct gene transfer into mouse muscle in vivo

Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine

Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine through 6 Months

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7). an exploratory analysis of a randomised controlled trial

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2. an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001). a phase 4, non-inferiority, single blind, randomised study

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

COVID-19 Vaccination and Glomerulonephritis

Definition and classification of chronic kidney disease. a position statement from Kidney Disease. Improving Global Outcomes (KDIGO)

Diagnosis, evaluation, and management of acute kidney injury. a KDIGO summary (Part 1)

Acute kidney disease and renal recovery. consensus report of the Acute Disease Quality Initiative

Acute kidney injury in patients hospitalized with COVID-19

Minimal Change Disease With Severe Acute Kidney Injury Following the Oxford-AstraZeneca COVID-19 Vaccine. A Case Report

New-onset Nephrotic Syndrome after Janssen COVID-19 Vaccination. a Case Report and Literature Review

Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine

An Additional Case of Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine

Minimal change disease and acute kidney injury following the Pfizer-BioNTech COVID-19 vaccine

Minimal change disease following the Moderna mRNA-1273 SARS-CoV-2 vaccine

Post-vaccinal minimal change disease

Minimal change disease soon after Pfizer-BioNTech COVID-19 vaccination

Minimal Change Disease After First Dose of Pfizer-BioNTech COVID-19 Vaccine. A Case Report and Review of Minimal Change Disease Related to COVID-19 Vaccine

Nephrotic syndrome and acute kidney injury following CoronaVac anti-SARS-CoV-2 vaccine

A case of membranous nephropathy following Pfizer-BioNTech mRNA vaccination against COVID-19

Membranous nephropathy following anti-COVID-19 mRNA vaccination

Histologic correlates of gross hematuria following Moderna COVID-19 vaccine in patients with IgA nephropathy

Is COVID-19 vaccination unmasking glomerulonephritis? Kidney Int

IgA nephropathy presenting as macroscopic hematuria in 2 pediatric patients after receiving the Pfizer COVID-19 vaccine

De novo vasculitis after mRNA-1273 (Moderna) vaccination. Kidney Int

Anti-GBM nephritis with mesangial IgA deposits after SARS-CoV-2 mRNA vaccination

A case of ANCA-associated vasculitis after AZD1222 (Oxford-AstraZeneca) SARS-CoV-2 vaccination. casualty or causality? Kidney Int

ANCA-Associated Vasculitis Presenting With Rhabdomyolysis and Pauci-Immune Crescentic Glomerulonephritis After Pfizer-BioNTech COVID-19 mRNA Vaccination

ANCA glomerulonephritis after the Moderna COVID-19 vaccination

ANCA-Associated Vasculitis Following Pfizer-BioNTech COVID-19 Vaccine

Batal, I. Antineutrophil Cytoplasmic Autoantibody-Associated Glomerulonephritis Following the Pfizer-BioNTech COVID-19 Vaccine

De-novo Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Following the mRNA-1273 (Moderna) Vaccine for COVID-19

Granulomatous vasculitis after the AstraZeneca anti-SARS-CoV-2 vaccine

A Case of Acute Interstitial Nephritis After Two Doses of the BNT162b2 SARS-CoV-2 Vaccine

Minimal change disease following vaccination for SARS-CoV-2

Relapse of primary membranous nephropathy after inactivated SARS-CoV-2 virus vaccination

Gross hematuria following SARS-CoV-2 vaccination in patients with IgA nephropathy

Thrombotic Thrombocytopenic Purpura after Ad26.COV2-S Vaccination

Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine

First diagnosis of thrombotic thrombocytopenic purpura after SARS-CoV-2 vaccine-Case report

Thrombotic Thrombocytopenic Purpura Presentation in an Elderly Gentleman Following COVID Vaccine Circumstances

Acquired thrombotic thrombocytopenic purpura following Pfizer COVID-19 vaccination

Acquired Thrombotic Thrombocytopenic Purpura Following BNT162b2 mRNA Coronavirus Disease Vaccination in a Japanese Patient

Leukocytoclastic vasculitis and acute renal failure following inactivated SARS-CoV-2 vaccine

Vaccine-induced immune thrombotic thrombocytopenia following AstraZeneca (ChAdOx1 nCOV-19) vaccine-A case report

New-Onset Kidney Diseases after COVID-19 Vaccination. A Case Series

Minimal Change Disease

Effector and memory CTL differentiation

SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans

Quantifying the early immune response and adaptive immune response kinetics in mice infected with influenza A virus

Adaptive immunity to SARS-CoV-2 and COVID-19

Immunology of idiopathic nephrotic syndrome

Immune dysregulation in minimal change nephropathy

Renal macrophage activation and Th2 polarization precedes the development of nephrotic syndrome in Buffalo/Mna rats

mRNA vaccines-A new era in vaccinology

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

Nucleic acid sensing by T cells initiates Th2 cell differentiation

COVID-19 vaccines: Modes of immune activation and future challenges

Spectrum of podocytopathies in new-onset nephrotic syndrome following COVID-19 disease. a report of 2 cases

Acute kidney injury in critically ill patients with COVID-19. Intens

Viral RNA in the influenza vaccine may have contributed to the development of ANCA-associated vasculitis in a patient following immunisation

De Novo ANCA-Associated Vasculitis With Glomerulonephritis in COVID-19

Autoantibodies related to systemic autoimmune rheumatic diseases in severely ill patients with COVID-19

ANCA-associated vasculitis after COVID-19

Systems vaccinology of the BNT162b2 mRNA vaccine in humans

Toll-like receptor 2 induces Th17 myeloperoxidase autoimmunity while Toll-like receptor 9 drives Th1 autoimmunity in murine vasculitis

Cytotoxic T-lymphocyte elicited vaccine against SARS-CoV-2 employing immunoinformatics framework

Antiphospholipid antibodies and risk of post-COVID-19 vaccination thrombophilia. The straw that breaks the camel's back?

New-onset autoimmune phenomena post-COVID-19 vaccination

Thrombotic Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination

Immune thrombocytopenia following COVID-19 mRNA vaccine. casuality or causality?

Adenovirus-induced thrombocytopenia. the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance

Thrombotic Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

Anti-platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein

COVID-19 vaccine-related myositis